Sun Pharma signs voluntary licensing agreement with Eli Lilly for expanding access to Baricitinib to help alleviate the burden of Covid-19 in India

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company ("Lilly") for expanding access to Lilly's drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India.

Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The drug is approved by the Central Drugs Standard Control Organization (CDSCO) for restricted emergency use in India.

Kirti Ganorkar, CEO-India business, Sun Pharma, said, "Through this collaboration, we aim to join our forces with Lilly to accelerate access to baricitinib in India at a time when it is most needed. This is another step by Sun Pharma towards making more treatment options available to patients in India for dealing with the pandemic."

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.679.5 as compared to the previous close of Rs. 679.25. The total number of shares traded during the day was 219512 in over 4635 trades.

The stock hit an intraday high of Rs. 691 and intraday low of 678. The net turnover during the day was Rs. 150071771.

Source : Equity Bulls

Keywords